510(k) device
ECG-AI Pulmonary Hypertension (PH) 12-Lead algorithm (1020)
Anumana, Inc. · Pulmonary Hypertension Machine Learning-Based Notification Software (SAT, Class II) · First FDA decision Mar 28, 2026, newest Mar 28, 2026Heart failure
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
Breakthrough-designated
Device trials
52
Naming "ECG-AI"
MAUDE reports
0
Brand "ECG-AI", since 2015
PubMed studies
96
Mentioning "ECG-AI"
AI summary across all sources
Written by Claude (Anthropic's AI) from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- ECG-AI Pulmonary Hypertension (PH) 12-Lead algorithm (1020)Breakthrough510(k)
K252360 · Decided Mar 28, 2026 · 242 days after receipt
Device type: Pulmonary Hypertension Machine Learning-Based Notification Software (SAT) · Cardiology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "ECG-AI", any status and sponsor, newest update first.
- Artificial Intelligence-enabled Management of Atrial Fibrillation(ABLE-AF Trial)Pivotal-lookingNot yet recruiting
Korea University Anam HospitalAcademic, hospital or other
NCT07938281 · 1,006 participants (planned) · Start Dec 1, 2026 · Primary completion Dec 1, 2029
Device: ECG Analysis Software AiTiALVDD; ECG Analysis Software AiTiALVSD · For: AF - Atrial Fibrillation
Sites: Seoul, South Korea
- Monitoring Hyperkalemia Using Point-of-care AI-enabled ECG Device Among Patients With Chronic Kidney Disease Stages 3b-5Pivotal-lookingRecruiting
Peking University First HospitalAcademic, hospital or other
NCT06901960 · 1,066 participants (planned) · Start Apr 2, 2025 · Primary completion Dec 31, 2027
Device: A mobile artificial intelligence-enhanced electrocardiogram device estimating plasma potassium categories (<5 mmol/L, 5 - <5.5 mmol/L, 5.5 - <6.0 mmol/L and ≥ 6.0 mmol/L) · For: Chronic Kidney Disease (Stages 3b-5)
Sites: Beijing, China; Nanning, China; Wuhan, China
- Capitalizing on AI to CapTure Undiagnosed Structural Heart DiseasePivotal-lookingActive, not recruiting
Pierre EliasAcademic, hospital or other
NCT07843004 · 4,000 participants (planned) · Start Sep 16, 2026 · Primary completion Jun 1, 2027
Device: EHR Alert · For: Structural Heart Abnormality; Valve Heart Disease; Heart Diseases and 1 more
Sites: New York, New York
Idoven 1903 S.L.Not on our public-company list
NCT07479992 · 5,000 participants (planned) · Start Apr 28, 2026 · Primary completion Jan 2027
Device: Willem AI ECG assessment · For: Aortic Stenosis
Sites: Bonn, Germany; Munich, Germany
- Determining Efficacy of an Artificial Intelligence-based System for Heart Failure Detection Through Interpretation of Electrocardiograms (DECISION)Pivotal-lookingRecruiting
Idoven 1903 S.L.Not on our public-company list
NCT07113223 · 1,968 participants (planned) · Start Jul 23, 2025 · Primary completion Mar 2027
Device: Willem™ platform ECG assessment · For: Heart Failure; Cardiovascular Risk Factors
Sites: Madrid, Spain; Santander, Spain; Stockholm, Sweden · 5 sites in all
- Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary HypertensionPivotal-lookingRecruiting
Tempus AINot on our public-company list
NCT06911632 · 900 participants (planned) · Start Jul 23, 2025 · Primary completion May 2028
Device: ECG-based AI Device - Results Returned to Investigator; ECG-based AI Device - Results Not Returned to Investigator · For: Pulmonary Hypertension; Interstitial Lung Disease (ILD)
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 41 sites in all
Inha University HospitalAcademic, hospital or other
NCT07844434 · 300 participants (planned) · Start Nov 10, 2026 · Primary completion Aug 30, 2027
Device: SmartECG-EF · For: Heart Failure; Atrial Fibrillation (AF); Electrocardiogram
Sites: Incheon, South Korea
- A Study to Detect Advanced Liver Disease Via AI-enabled ElectrocardiogramPivotal-lookingCompleted
Mayo ClinicAcademic, hospital or other
NCT05782283 · 248 participants · Start Apr 18, 2023 · Primary completion Sep 1, 2025
Device: ACE (AI-Cirrhosis-ECG) 2.0 · For: Cirrhosis
Sites: Rochester, Minnesota
- Deployment and Evaluation of Artificial Intelligence Software for Electrocardiogram Analysis and Management in Primary CarePivotal-lookingEnrolling by invitation
Montreal Heart InstituteAcademic, hospital or other
NCT06637293 · 2,000 participants (planned) · Start Oct 2, 2025 · Primary completion Jan 2027
Device: DeepECG plateform diagnosis & recommendations · For: Primary Care Provider; Structural Heart Disease
Sites: Montreal, Canada
- VIZ ACCESS HCM - Multi-Site RegistryTerminated
Viz.ai, Inc.Not on our public-company list
NCT07103057 · 17 participants · Start Jun 13, 2025 · Primary completion Sep 17, 2026
Device: Viz HCM · For: Hypertrophic Cardiomyopathy
Sites: Atlanta, Georgia; Evanston, Illinois; Philadelphia, Pennsylvania
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "ECG-AI", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code SAT
1 reports: 0 malfunction, 1 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "ECG-AI"[tiab]. The summary above synthesizes these.
- Prediction of incident atrial fibrillation using deep learning, clinical models, and polygenic scores.
Jabbour G, Nolin-Lapalme A, Tastet O, et al. · Eur Heart J · 2024Research Support, Non-U.S. Gov't
- ECG-AI: electrocardiographic artificial intelligence model for prediction of heart failure.
Akbilgic O, Butler L, Karabayir I, et al. · Eur Heart J Digit Health · 2021
- ECG-Based Deep Learning and Clinical Risk Factors to Predict Atrial Fibrillation.
Khurshid S, Friedman S, Reeder C, et al. · Circulation · 2022Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Implementing ECG-AI in Clinical Care: From Pixel to Practice.
Yoon M, You SC · J Am Coll Cardiol · 2025Editorial
- Generalizability of electrocardiographic artificial intelligence.
Karabayir I, Akbilgic O · NPJ Cardiovasc Health · 2025Review
- AI-based preeclampsia detection and prediction with electrocardiogram data.
Butler L, Gunturkun F, Chinthala L, et al. · Front Cardiovasc Med · 2024
- Time-Dependent ECG-AI Prediction of Fatal Coronary Heart Disease: A Retrospective Study.
Butler L, Ivanov A, Celik T, et al. · J Cardiovasc Dev Dis · 2024
- Artificial Intelligence-Enabled ECG: Physiologic and Pathophysiologic Insights and Implications.
Kashou AH, Adedinsewo DA, Siontis KC, et al. · Compr Physiol · 2022Research Support, N.I.H., Extramural
- Artificial intelligence-enabled prediction of chemotherapy-induced cardiotoxicity from baseline electrocardiograms.
Yagi R, Goto S, Himeno Y, et al. · Nat Commun · 2024Research Support, Non-U.S. Gov't
- The Emerging Role of ECG-AI as a Digital Risk Biomarker for Incident Heart Failure.
Oikonomou EK · J Am Coll Cardiol · 2026Editorial
- Subclinical Atrial Fibrillation: A Silent Threat with Uncertain Implications.
Kashou AH, Adedinsewo DA, Noseworthy PA · Annu Rev Med · 2022Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Phenotypic Selectivity of Artificial Intelligence-Enhanced Electrocardiography in Cardiovascular Diagnosis and Risk Prediction.
Croon PM, Dhingra LS, Biswas D, et al. · Circulation · 2025
Other devices of this type
Also filed under product code SAT.
- Tempus ECG-PHTempus AI, Inc. · 510(k) 2026
- CorVista System with PH Add-OnAnalytics For Life, Inc. · 510(k) 2024
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.